Luminex CEO Patrick Balthrop said this week that the company is "well into the alpha stage" of development for its high-volume, low-multiplex, cartridge-based clinical diagnostic system, dubbed Project Aries.

As such, Luminex's R&D spend increased by approximately 26 percent in the first quarter, a trend that it sees continuing over the next several quarters — though at a slightly slower pace — as it prepares the sample-to-answer testing platform for beta testing and possible commercialization next year, Balthrop said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.